|Values are valid only on day of printing.|
Persistent infections with high risk human papillomavirus (HPV) genotypes (16, 18, 31, 33 and 51) are associated with cervical, vaginal, vulvar, and head and neck malignancies. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) have shown better disease-specific survival and overall survival when compared to HPV-negative cases of OPSCC.
Detection of human papillomavirus DNA from high-risk genotypes (16, 18, 31, 33 and 51)
This test, when not accompanied by a pathology consultation request, will be answered as either positive or negative. If additional interpretation/analysis is needed, please request test 70012 / Pathology Consultation along with this test.
The probe set used in this human papillomavirus (HPV) DNA in situ hybridization (ISH) test cannot detect all potential HPV serotypes that are associated with oropharyngeal squamous cell carcinoma. Following a negative HPV High Risk DNA ISH result, a more sensitive test, High Risk HPV RNA ISH, could be performed, if clinically indicated. The RNA ISH test is only available in the context of a pathology consultation (test 70012 / Pathology Consultation).
1. Kelesidis T, Aish L, Steller MA, et al: Human papillomavirus (HPV) detection using in situ hybridization in histologic samples. Am J Clin Pathol 2011;136:119-127
2. Lee WT, Tubbs RR, Teker AM, et al: Use of in situ hybridization to detect human papillomavirus in head and neck squamous cell carcinoma patients without a history of alcohol or tobacco use. Arch Pathol Lab Med 2008;132:1653-1656
3. Birner P, Bachtiary B, Dreier B, et al: Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions. Mod Pathol 2001;14(7):702-709